Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number...
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
2013
|